STEAP1: a promising target in prostate cancer therapy.

IF 17.5 1区医学 Q1 ONCOLOGY

Trends in cancer Pub Date : 2025-06-16 DOI:10.1016/j.trecan.2025.05.007

Rohit Singh, Jon Amund Kyte

引用次数: 0

Abstract

The unmet therapeutic need in prostate cancer (PCa), a disease that remains largely incurable after metastasis, underscores the urgency for new treatments. STEAP1 (six transmembrane epithelial antigen of prostate 1) is a cell surface protein highly expressed in >85% prostate tumors but shows little to no presence in normal tissues, making it a promising candidate for targeted therapy. Here, we summarize and discuss recent findings that underscore the promising role of STEAP1 in PCa therapy.

查看原文本刊更多论文

STEAP1：前列腺癌治疗的一个有希望的靶点。

前列腺癌（PCa）是一种转移后基本上无法治愈的疾病，其治疗需求尚未得到满足，这突显了开发新疗法的紧迫性。STEAP1（前列腺6跨膜上皮抗原1）是一种细胞表面蛋白，在85%的前列腺肿瘤中高表达，但在正常组织中几乎不存在，这使其成为靶向治疗的有希望的候选蛋白。在这里，我们总结并讨论了强调STEAP1在前列腺癌治疗中有希望作用的最新发现。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Trends in cancer Medicine-Oncology

CiteScore

28.50

自引率

0.50%

发文量

138

期刊介绍： Trends in Cancer, a part of the Trends review journals, delivers concise and engaging expert commentary on key research topics and cutting-edge advances in cancer discovery and medicine. Trends in Cancer serves as a unique platform for multidisciplinary information, fostering discussion and education for scientists, clinicians, policy makers, and patients & advocates.Covering various aspects, it presents opportunities, challenges, and impacts of basic, translational, and clinical findings, industry R&D, technology, innovation, ethics, and cancer policy and funding in an authoritative yet reader-friendly format.